Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 H167_N173del FGFR2 L617F |
Therapy | Zoligratinib |
Indication/Tumor Type | intrahepatic cholangiocarcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 H167_N173del FGFR2 L617F | intrahepatic cholangiocarcinoma | predicted - resistant | Zoligratinib | Case Reports/Case Series | Actionable | In a clinical study, a patient with intrahepatic cholangiocarcinoma harboring FGFR2 H167_N173del developed resistance to Debio 1347 treatment after initial response, FGFR2 L617F was identified as an acquired mutation at disease progression (J Clin Oncol 38, 2020 (suppl 4; abstr 567)). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma. | Full reference... |